Allurion, maker of a swallowable gastric balloon designed to facilitate weight loss, has partnered with Medtronic in a pilot agreement to distribute the device in Central and Eastern Europe, the Middle East and Africa.
The 12-month collaboration, intended to expand access to the device, enables Allurion to offer the balloon and accelerate use of its Iris artificial intelligence (AI) platform for managing bariatric surgery patients.
The Allurion system combines the balloon, which the patient swallows without surgery, endoscopy or anesthesia, with a remote patient monitoring solution powered by the Allurion Iris AI Platform and the company’s proprietary behavioral change program. The Allurion Virtual Care Suite is also available to providers as a standalone product to help monitor and manage weight loss therapy for patients, regardless of whether they are treated with the gastric balloon, surgery or medical or nutritional approaches, the company said.
In addition to expanding access to the gastric balloon, it is hoped that the partnership will help accelerate adoption of the Iris AI Platform as a standalone offering to streamline the management of patients undergoing bariatric surgery and potentially improve outcomes.
To read more, CLICK HERE.